Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cardiac Toxicity
Interventions: BIOLOGICAL: trastuzumab|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: lapatinib ditosylate|DRUG: paclitaxel|GENETIC: gene expression analysis|GENETIC: reverse transcriptase-polymerase chain reaction|OTHER: fluorophotometry|OTHER: laboratory biomarker analysis|OTHER: mass spectrometry|PROCEDURE: adjuvant therapy|PROCEDURE: quality-of-life assessment
Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)